Nucleus Genomics Launches New DNA Analysis Product
Nucleus Genomics launched a DNA analysis product aimed at expanding access to the benefits of personalized medicine.
Read MorePosted by Andy Lundin | Mar 25, 2024 | Molecular Diagnostics |
Nucleus Genomics launched a DNA analysis product aimed at expanding access to the benefits of personalized medicine.
Read MorePosted by Andy Lundin | Mar 22, 2024 | Unknown Origin & Other Cancer Types |
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.
Read MorePosted by Andy Lundin | Mar 18, 2024 | Disease States |
A study provides evidence that the novel monoclonal antibody reveals loss of protein function linked to ALS and FTD before symptoms appear.
Read MorePosted by Chris Wolski | Mar 15, 2024 | Miscellaneous |
Data shows how computational indexing combined with a systematic literature review can be used to characterize gene-disease relationships.
Read MorePosted by Andy Lundin | Mar 12, 2024 | Company News |
Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext and CancerNext-Expanded assays.
Read More